PRPH ProPhase Labs Inc

ProPhase Labs to Present at the Virtual Fall Investor Summit on Monday, November 16, 2020 at 2:30 p.m. Eastern Time

ProPhase Labs to Present at the Virtual Fall Investor Summit on Monday, November 16, 2020 at 2:30 p.m. Eastern Time

DOYLESTOWN, PA , Nov. 10, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase Labs”), a diversified medical science and technology company, today announced that management will present at the Virtual Fall Investor Summit taking place November 16th – 18th, 2020.

ProPhase Labs CEO Ted Karkus is scheduled to host a virtual presentation during the conference and will also participate in one-on-one meetings throughout the day. Management will highlight its recent formation of ProPhase Diagnostics, which just completed the acquisition of a Clinical Laboratory Improvement Amendments (“CLIA”) accredited laboratory in Old Bridge, New Jersey, and introduce Steven Kamalic, who was recently appointed COO of ProPhase Diagnostics. Steven is an 18-year industry veteran who recently oversaw a prominent east coast CLIA accredited laboratory and achieved record annual revenue growth to $160 million during his ten-year tenure.

Virtual Fall Investor Summit

Date:Monday, November 16, 2020
Time:2:30 p.m. EST, 11:30 a.m. PST
Webcast:
Location:Virtual

For more information or to schedule a one-on-one meeting with ProPhase Labs management, please contact your conference representative or you may also email your request to  or call Chris Tyson at (949) 491-8235.

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. It’s dietary supplement line of products, TK Supplements, has extensive distribution in major FDM (Food, Drug and Mass) retailers including Walmart, Walgreens, CVS and RITE-AID. The Company’s recently formed wholly-owned subsidiary, ProPhase Diagnostics, Inc., is a rapidly developing CLIA laboratory business that offers COVID-19 and other Respiratory Pathogen Panel (RPP) testing services. ProPhase Labs is dedicated to creating sustainable value for shareholders over the long-term through growth of its existing businesses. It is also continuing to explore strategic investments and additional acquisition opportunities. For more information visit us at .

Investor Contact:

Chris Tyson

Managing Director

MZ Group - MZ North America

949-491-8235



EN
10/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE

ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Stud...

ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology Peer-Reviewed Study Conducted in Collaboration with Mayo Clinic Demonstrates 100% Sensitivity and Strong Predictive Power for Esophageal Cancer Progression Early Access Programs and Physician Onboarding Initiatives Expected to Begin in Early 2026 UNIONDALE, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) today announced that its study, “Assessing Risk of Progression in Barrett’s Esophagus Using a Mass-Spectrometry-Based Prot...

 PRESS RELEASE

ProPhase Labs Engages RedChip Companies to Lead Investor Relations Eff...

ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it has engaged RedChip Companies (“RedChip”) to lead its investor relations efforts. “We are entering a transformative phase for ProPhase,” said Ted Karkus, CEO and Chairman of ProPhase Labs. “With the imminent commercialization of our BE-Smart™ esophageal cancer diagnostic, continued expansion of our Nebula Genom...

 PRESS RELEASE

ProPhase Labs to Present at the 2025 ThinkEquity Conference

ProPhase Labs to Present at the 2025 ThinkEquity Conference UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be participating in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Ted Karkus, CEO and Chairman of ...

 PRESS RELEASE

ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Te...

ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating Potential UNIONDALE, NY, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in C...

 PRESS RELEASE

PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CR...

PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE COVID-19 TESTING LABORATORY SUBSIDIARIES FILE FOR BANKRUPCTY PROTECTION UNIONDALE, NY, Sept. 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced that its three COVID-19 testing laboratory companies filed for reorganization under Chapter 11 in United States Bankruptcy Court for the District of New Jersey, advancing the Crown Medical Collections initiat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch